|
1
|
Yung KW, Yung TT, Chung CY, Tong GT, Liu
Y, Henderson J, Welbeck D and Oseni S: Principles of cancer
staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
|
|
2
|
Zheng YF, Tan LK, Tan BH, Sterling H and
Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol.
1:17–26. 2015.
|
|
3
|
Dobson PR, Brown BL, Beck D, Yang H, Zhou
J and Voon YL: Management of surgical oncologic emergencies. Asian
Pac J Surg Oncol. 1:59–72. 2015.
|
|
4
|
Li WW, Dai ZY, Wan HG, Yao LZ, Zhu J, Li
CL, Wang XJ, Pan J and Chen LZ: Endovascular implantation of
iodine-125 seeds strand and portal vein stenting followed by
transcatheter arterial chemoembolization combined therapy with
sorafenib for hepatocellular carcinoma with main portal vein tumor
thrombus. Zhonghua Yi Xue Za Zhi. 96:1838–1842. 2016.(In Chinese).
PubMed/NCBI
|
|
5
|
Dinh VY, Bhatia S, Narayanan G, Yrizarry
J, Savaraj N, O'Brien C, Martin P and Feun L: Pilot study of
intrahepatic artery chemotherapy in combination with sorafenib in
hepatocellular carcinoma. Anticancer Res. 36:3555–3563.
2016.PubMed/NCBI
|
|
6
|
Hatooka M, Kawaoka T, Aikata H, Morio K,
Kobayashi T, Hiramatsu A, Imamura M, Kawakami Y, Murakami E, Waki
K, et al: Comparison of outcome of hepatic arterial infusion
chemotherapy and sorafenib in patients with hepatocellular
carcinoma refractory to transcatheter arterial chemoembolization.
Anticancer Res. 36:3523–3529. 2016.PubMed/NCBI
|
|
7
|
Cahill T, Chen XL, Lee JW, Weiss M, Chang
VT and Cella D: Principles of radiofrequency ablation for cancer.
Asian Pac J Surg Oncol. 1:47–58. 2015.
|
|
8
|
Ghoneum M, Felo N, Nwaogu OM, Fayanju IY,
Jeffe JA and Margenthaler DB: Clinical trials in surgical oncology.
Asian Pac J Surg Oncol. 1:73–82. 2015.
|
|
9
|
Sterling B, Cole R, Jen KK and Shieh JS:
Surgical oncology in the elderly. Asian Pac J Surg Oncol. 1:83–100.
2015.
|
|
10
|
Mellotte G, Maher V, Devitt PG, Shin VY
and Leung CP: Minimally invasive surgical oncology: state of the
art. Asian Pac J Surg Oncol. 1:101–112. 2015.
|
|
11
|
Sheta E, El-Kalla F, El-Gharib M, Kobtan
A, Elhendawy M, Abd-Elsalam S, Mansour L and Amer I: Comparison of
single-session transarterial chemoembolization combined with
microwave ablation or radiofrequency ablation in the treatment of
hepatocellular carcinoma: a randomized-controlled study. Eur J
Gastroenterol Hepatol. 28:1198–1203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujiwara H, Arai Y, Ishii H and Kanazawa
S: Computed tomography-guided radiofrequency ablation for
sub-diaphragm hepatocellular carcinoma: safety and efficacy of
inducing an artificial pneumothorax. Acta Med Okayama. 70:189–195.
2016.PubMed/NCBI
|
|
13
|
Sohn W, Kang TW, Choi SK, Jung SH, Lee MW,
Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, et al: Effect of oral
antiviral treatment on long-term outcomes of radiofrequency
ablation therapy for hepatitis B virus-related hepatocellular
carcinoma. Oncotarget. 14:17–18. 2016.
|
|
14
|
Borentain P, Gregoire E, Louis G and
Gerolami R: Successful liver transplantation for hepatocellular
carcinoma following down-staging using sorafenib single therapy.
Liver Int. 36:13932016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shiozawa K, Watanabe M, Ikehara T, Kogame
M, Kikuchi Y, Igarashi Y and Sumino Y: Therapeutic evaluation of
sorafenib for hepatocellular carcinoma using contrast-enhanced
ultrasonography: preliminary result. Oncol Lett. 12:579–584.
2016.PubMed/NCBI
|
|
16
|
Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma
KS, Li XW and Bie P: Adjuvant sorafenib after heptectomy for
Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma
patients. World J Gastroenterol. 22:5384–5392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng J, Lv L and Mei ZC: Efficacy and
safety of transarterial chemoembolization plus sorafenib for early
or intermediate stage hepatocellular carcinoma: a systematic review
and meta-analysis of randomized controlled trials. Clin Res Hepatol
Gastroenterol. 20:18–19. 2016.
|
|
18
|
Ishikawa T, Kubota T, Abe S, Watanabe Y,
Sugano T, Inoue R, Iwanaga A, Seki K, Honma T and Yoshida T:
Hepatic arterial infusion chemotherapy with cisplatin before
radical local treatment of early hepatocellular carcinoma (JIS
score 0/1) improves survival. Ann Oncol. 25:1379–1384. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo W, He X, Li Z and Li Y: Combination of
transarterial chemoembolization (TACE) and radiofrequency ablation
(RFA) vs. surgical resection (SR) on survival outcome of early
hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology.
62:710–714. 2015.PubMed/NCBI
|
|
20
|
Zhu AX, Kang YK, Rosmorduc O, Evans TR,
Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, et al:
Biomarker analyses of clinical outcomes in patients with advanced
hepatocellular carcinoma treated with sorafenib with or without
erlotinib in the SEARCH trial. Clin Cancer Res. 24:182–183.
2016.
|
|
21
|
Lamarca A, Mendiola M, Bernal E, Heredia
V, Díaz E, Miguel M, Pastrian LG, Burgos E, Feliu J and Barriuso J:
Tumoural expression of connective tissue growth factor (CTGF)
impacts on survival in patients diagnosed with hepatocellular
carcinoma (HCC). Curr Cancer Drug Targets. 15:435–444. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang
X, Li J, Qiao H, Ni S and Sun X: 2-Methoxyestradiol synergizes with
sorafenib to suppress hepatocellular carcinoma by simultaneously
dysregulating hypoxia-inducible factor-1 and −2. Cancer Lett.
355:96–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei
J, Sheng Y, Zheng Y, Yu J, Xie L, et al: Osteopontin promotes
epithelial-mesenchymal transition of hepatocellular carcinoma
through regulating vimentin. Oncotarget. 7:12997–13012. 2016.
View Article : Google Scholar : PubMed/NCBI
|
